Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway

Reproductive Biology and Endocrinology

Volumn 8, Issue , 2010, Pages

  Guo, Jian ^a,b   Schally, Andrew V ^c   Zarandi, Marta ^c   Varga, Jozsef ^c   Leung, Peter C K ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; EPIDERMAL GROWTH FACTOR; GONADORELIN ANTAGONIST; GROWTH HORMONE RELEASING FACTOR RECEPTOR; JMR 132; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; DRUG DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; GHRH(1 29)NH2, PHACTYR(1) ARG(2) P(H)E(4 CL)(6) ALA(8) TYR(ME)(10) HIS(11) ABU(15) HIS(20) NLE(27) ARG(28) HLCR(29); GHRH(1-29)NH2, PHACTYR(1)-ARG(2)-P(H)E(4-CL)(6)-ALA(8)-TYR(ME)(10)-HIS(11)-ABU(15)-HIS(20)-NLE(27)-ARG(28)-HLCR(29)-; GROWTH HORMONE RELEASING FACTOR; HORMONE ANTAGONIST; HORMONE RECEPTOR; NEUROPEPTIDE RECEPTOR; SERMORELIN; SOMATOTROPIN RELEASING HORMONE RECEPTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HUMAN; HUMAN CELL; OVARY CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ADENOCARCINOMA; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH HORMONE-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NEUROPEPTIDE; RECEPTORS, PITUITARY HORMONE-REGULATING HORMONE; RNA, SMALL INTERFERING; SERMORELIN; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 77952740229     PISSN: None     EISSN: 14777827     Source Type: Journal    
DOI: 10.1186/1477-7827-8-54     Document Type: Article

References (51)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Partridge EE, Barnes MN. Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999, 49:297-320. 10.3322/canjclin.49.5.297, 11198956.
3. Schally AV, Varga JL, Engel JB. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer. Nat Clin Pract Endocrinol Metab 2008, 4:33-43. 10.1038/ncpendmet0677, 18084344.
4. Gelato M. Growth hormone releasing hormone: clinical perspectives revisited. Endocrinologist 2005, 15:159-164.
5. Szepeshazi K, Schally AV, Groot K, Armatis P, Hebert F, Halmos G. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit in vivo proliferation of experimental pancreatic cancers and decrease IGF-II levels in tumours. Eur J Cancer 2000, 36:128-136. 10.1016/S0959-8049(99)00230-0, 10741306.
6. Szepeshazi K, Schally AV, Groot K, Armatis P, Halmos G, Herbert F, Szende B, Varga JL, Zarandi M. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br J Cancer 2000, 82:1724-1731. 10.1054/bjoc.2000.1223, 2374518, 10817510.
7. Jungwirth A, Schally AV, Pinski J, Halmos G, Groot K, Armatis P, Vadillo-Buenfil M. Inhibition of in vivo proliferation of androgen-independent prostate cancers by an antagonist of growth hormone-releasing hormone. Br J Cancer 1997, 75:1585-1592. 2223520, 9184172.
8. Lamharzi N, Schally AV, Koppan M, Groot K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 1998, 95:8864-8868. 10.1073/pnas.95.15.8864, 21168, 9671770.
9. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 2003, 100:1250-1255. 10.1073/pnas.0337496100, 298759, 12538852.
10. Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice. Clin Cancer Res 2005, 11:49-57.
11. Kahan Z, Varga JL, Schally AV, Rekasi Z, Armatis P, Chatzistamou L, Czompoly T, Halmos G. Antagonists of growth hormone-releasing hormone arrest the growth of MDA-MB-468 estrogen-independent human breast cancers in nude mice Breast. Cancer Res Treat 2000, 60:71-79.
12. Chatzistamou I, Schally AV, Varga JL, Groot K, Busto R, Armatis P, Halmos G. Inhibition of growth and metastases of MDA-MB-435 human estrogen-independent breast cancers by an antagonist of growth hormone-releasing hormone. Anticancer Drugs 2001, 12:761-768. 10.1097/00001813-200110000-00008, 11593058.
13. Jungwirth A, Schally AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc Natl Acad Sci USA 1997, 94:5810-5813. 10.1073/pnas.94.11.5810, 20862, 9159156.
14. Kiaris H, Schally AV, Varga JL. Antagonists of growth hormone-releasing hormone inhibit the growth of U-87MG human glioblastoma in nude mice. Neoplasia 2000, 2:242-250. 10.1038/sj.neo.7900074, 1507563, 10935510.
15. Pinski J, Schally AV, Groot K, Halmos G, Szepeshazi K, Zarandi M, Armatis P. Inhibition of growth of human osteosarcomas by antagonists of growth hormone-releasing hormone. J Natl Cancer Inst 1995, 87:1787-1794. 10.1093/jnci/87.23.1787, 7473836.
16. Braczkowski R, Schally AV, Plonowski A, Varga JL, Groot K, Krupa M, Armatis P. Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone: effects on insulin-like growth factor II. Cancer 2002, 95:1735-1745. 10.1002/cncr.10865, 12365022.
17. Hohla F, Schally AV, Szepeshazi K, Varga JL, Buchholz S, Köster F, Heinrich E, Halmos G, Rick FG, Kannadka C, Datz C, Kanashiro CA. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc Natl Acad Sci USA 2006, 103:14513-8. 10.1073/pnas.0605309103, 1599991, 16983095.
18. Szereday Z, Schally AV, Varga JL, Kanashiro CA, Hebert F, Armatis P, Groot K, Szepeshazi K, Halmos G, Busto R. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res 2003, 63:7913-7919.
19. Keller G, Schally AV, Groot K, Toller GL, Havt A, Köster F, Armatis P, Halmos G, Zarandi M, Varga JL, Engel JB. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone. Proc Natl Acad Sci USA 2005, 102:10628-33. 10.1073/pnas.0504102102, 1180787, 16027368.
20. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 2001, 86:2144-52. 10.1210/jc.86.5.2144, 11344219.
21. Engel JB, Keller G, Schally AV, Toller GL, Groot K, Havt A, Armatis P, Zarandi M, Varga JL, Halmos G. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone. J Clin Endocrinol Metab 2005, 90:3614-3621. 10.1210/jc.2004-2179, 15784701.
22. Plonowski A, Schally AV, Varga JL, Rekasi Z, Hebert F, Halmos G, Groot K. Potentiation of the inhibitory effect of growth hormone-releasing hormone antagonists on PC-3 human prostate cancer by bombesin antagonists indicative of interference with both IGF and EGF pathways. Prostate 2000, 44:172-80. 10.1002/1097-0045(20000701)44:2<172::AID-PROS10>3.0.CO;2-Z, 10881027.
23. Jaffe CA, DeMott-Friberg R, Frohman LA, Barkan AL. Suppression of growth hormone (GH) hypersecretion due to ectopic GH-releasing hormone (GHRH) by a selective GHRH antagonist. J Clin Endocrinol Metab 1997, 82:634-637. 10.1210/jc.82.2.634, 9024267.
24. Szepeshazi K, Schally AV, Armatis P, Groot K, Hebert F, Feil A, Varga JL, Halmos G. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 2001, 142:4371-8. 10.1210/en.142.10.4371, 11564700.
25. Plonowski A, Schally AV, Letsch M, Krupa M, Hebert F, Busto R, Groot K, Varga JL. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor. Prostate 2002, 52:173-182. 10.1002/pros.10105, 12111694.
26. Rekasi Z, Varga JL, Schally AV, Halmos G, Armatis P, Groot K, Czompoly T. Antagonists of GHRH decrease production of GH and IGF-I in MXT mouse mammary cancers and inhibit tumor growth. Endocrinology 2000, 141:2120-2128. 10.1210/en.141.6.2120, 10830299.
27. Rekasi Z, Czompoly T, Schally AV, Halmos G. Isolation and sequencing of cDNAs for splice variants of growth hormone releasing hormone receptors from human cancers. Proc Natl Acad Sci USA 2000, 97:10561-10566. 10.1073/pnas.180313297, 27064, 10962031.
28. Plonowski A, Schally AV, Busto R, Krupa M, Varga JL, Halmos G. Expression of growth hormone-releasing hormone (GHRH) and splice variants of GHRH receptors in human experimental prostate cancers Peptides. 2002, 23:1127-1133.
29. Busto R, Schally AV, Varga JL, Garcia-Fernandez MO, Groot K, Armatis P, Szepeshazi K. The expression of growth hormonereleasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc Natl Acad Sci USA 2002, 99:11866-11871. 10.1073/pnas.182433099, 129360, 12186980.
30. Busto R, Schally AV, Braczkowski R, Plonowski A, Krupa M, Groot K, Armatis P, Varga JL. Expression of mRNA for growth hormone-releasing hormone and splice variants of GHRH receptors in human malignant bone tumors. Regul Pept 2002, 108:47-53. 10.1016/S0167-0115(02)00109-X, 12220726.
31. Garcia-Fernandez MO, Schally AV, Varga JL, Groot K, Busto R. The expression of growth hormone-releasing hormone (GHRH) and its receptor splice variants in human breast cancer lines; the evaluation of signaling mechanisms in the stimulation of cell proliferation. Breast Cancer Res Treat 2003, 77:15-26. 10.1023/A:1021196504944, 12602901.
32. Kiaris H, Schally AV, Busto R, Halmos G, Artavanis-Tsakonas S, Varga JL. Expression of a splice variant of the receptor for GHRH in 3T3 fibroblasts activates cell proliferation responses to GHRH analogs. Proc Natl Acad Sci USA 2002, 99:196-200. 10.1073/pnas.012590999, 117538, 11773624.
33. Kiaris H, Chatzistamou I, Schally AV, Halmos G, Varga JL, Koutselini H, Kalofoutis A. Ligand-dependent and -independent effects of splice variant 1 of growth hormonereleasinghormone receptor. Proc Natl Acad Sci USA 2003, 100:9512-9517. 10.1073/pnas.1533185100, 170949, 12867592.
34. Barabutis N, Tsellou E, Schally AV, Kouloheri S, Kalofoutis A, Kiaris H. Stimulation of proliferation of MCF-7 breastcancer cells by a transfected splice variant of growth hormone releasing hormone receptor. Proc Natl Acad Sci USA 2007, 104:5575-5579. 10.1073/pnas.0700407104, 1838504, 17372203.
35. Seitz S, Hohla F, Schally AV, Moder A, Engel JB, Horn F, Varga J, Zarandi M, Ortmann O, Köster F, Buchholz S. Inhibition of estrogen receptor positive and negative breast cancer cell lines with a growth hormone-releasing hormone antagonist. Oncol Rep 2008, 20:1289-94.
36. Buchholz S, Schally AV, Engel JB, Hohla F, Heinrich E, Koester F, Varga JL, Halmos G. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc Natl Acad Sci USA 2007, 104:1943-6. 10.1073/pnas.0610860104, 1794297, 17261802.
37. Barabutis N, Schally AV. Antioxidant activity of growth hormone-releasing hormone antagonists in LNCaP human prostate cancer line. Proc Natl Acad Sci USA 2008, 105:20470-5. 10.1073/pnas.0811209106, 2629286, 19075233.
38. Barabutis N, Schally AV. Knocking down gene expression for growth hormone-releasing hormone inhibits proliferation of human cancer cell lines. Br J Cancer 2008, 98:1790-6. 10.1038/sj.bjc.6604386, 2410108, 18506184.
39. Volakaki AA, Lafkas D, Kassi E, Schally AV, Papavassiliou AG, Kiaris H. Essential role of p21/waf1 in the mediation of the antiproliferative effects of GHRH antagonist JMR-132. J Mol Endocrinol 2008, 41:389-92. 10.1677/JME-08-0106, 18765563.
40. Csernus V, Schally AV, Groot K. Antagonistic analogs of growth hormone releasing hormone (GHRH) inhibit cyclic AMP production of human cancer cell lines in vitro. Peptides 1999, 20:843-50. 10.1016/S0196-9781(99)00071-6, 10477085.
41. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Suppression of growth of H-69 small cell lung carcinoma by antagonists of growth hormone releasing hormone and bombesin is associated with an inhibition of protein kinase C signaling. Int J Cancer 2004, 112:570-6. 10.1002/ijc.20437, 15382037.
42. Kanashiro CA, Schally AV, Groot K, Armatis P, Bernardino AL, Varga JL. Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin. Proc Natl Acad Sci USA 2003, 100:15836-41. 10.1073/pnas.2536558100, 307654, 14660794.
43. Zhao L, Yano T, Osuga Y, Nakagawa S, Oishi H, Wada-Hiraike O, Tang X, Yano N, Kugu K, Schally AV, Taketani Y. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone. Int J Oncol 2008, 32:593-601.
44. Chan JK, Pham H, You XJ, Cloven NG, Burger RA, Rose GS, Van Nostrand K, Korc M, Disaia PJ, Fan H. Suppression of ovarian cancer cell tumorigenicity and evasion of Cisplatin resistance using a truncated epidermal growth factor receptor in a rat model. Cancer Res 2005, 65:3243-3248. 10.1158/0008-5472.CAN-05-0137, 15833856.
45. Berchuck A, Rodriguez GC, Kamel A, Dodge RK, Soper JT, Clarke-Pearson DL, Bast RC. Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer. I. Correlation of receptor expression with prognostic factors in patients with ovarian cancer. Am J Obstet Gynecol 1991, 164:669-674.
46. Hackel PO, Zwick E, Prenzel N, Ullrich A. Epidermal growth factor receptors: critical mediators of multiple receptor pathways. Curr Opin Cell Biol 1999, 11:184-18. 10.1016/S0955-0674(99)80024-6, 10209149.
47. Maihle NJ, Baron AT, Barrette BA, Boardman CH, Christensen TA, Cora EM, Faupel-Badger JM, Greenwood T, Juneja SC, Lafky JM, Lee H, Reiter JL, Podratz KC. EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res 2002, 107:247-258.
48. Zhou C, Qiu L, Sun Y, Healey S, Wanebo H, Kouttab N, Di W, Yan B, Wan Y. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells. Int J Oncol 2006, 29:269-78.
49. Kanashiro CA, Schally AV, Varga JL, Hammann B, Halmos G, Zarandi M. Antagonists of growth hormone releasing hormone and bombesin inhibit the expression of EGF/HER receptor family in H-69 small cell lung carcinoma. M Cancer Lett 2005, 226:123-131.
50. Kanashiro CA, Schally AV, Zarandi M, Hammann BD, Varga JL. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int J Oncol 2007, 30:1019-28.
51. Kermer P, Klöcker N, Labes M, Bähr M. Insulin-like growth factor-I protects axotomized rat retinal ganglion cells from secondary death via PI3-K-dependent Akt phosphorylation and inhibition of caspase-3 in vivo. J Neurosci 2000, 20:722-728.